Taysha Gene Therapies, Inc. SEC filings TSHA

Taysha Gene Therapies, Inc. has 401 filings in SEC EDGAR's recent list, going back to May 4, 2020. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders Apr 22, 2026 Dec 31, 2025
10-K Annual report Mar 19, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 21, 2025 Dec 31, 2024
10-K Annual report Feb 26, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 18, 2024 Dec 31, 2023
10-K Annual report Mar 19, 2024 Dec 31, 2023
ARS Annual report to shareholders May 8, 2023 Dec 31, 2022
10-K/A Amended annual report Apr 27, 2023 Dec 31, 2022
10-K Annual report Mar 28, 2023 Dec 31, 2022
10-K Annual report Mar 31, 2022 Dec 31, 2021
10-K Annual report Mar 3, 2021 Dec 31, 2020

Showing 11 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
TSHA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Dallas, TX
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1806310

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.